Compare Globus Medical Inc. Class A Common Stock (GMED) vs XP Inc. Class A Common Stock (XP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Globus Medical Inc. Class A Common Stock vs XP Inc. Class A Common Stock — how do they compare? Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B), while XP Inc. Class A Common Stock trades at $30.06 (market cap $15.93B). The key difference: XP Inc. Class A Common Stock is the larger of the two by market cap, and XP Inc. Class A Common Stock pays a 0.64% dividend while Globus Medical Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Globus Medical Inc. Class A Common Stock for 0 Days and XP Inc. Class A Common Stock for 5 Days on average.
| GMED | XP | |
|---|---|---|
Market Cap | $10.25B | $15.93B |
Volume | 1,108,124 | 10,243,374 |
Sector | Health | Financials |
52-Week High | $96.82 | $32.60 |
52-Week Low | $58.33 | $14.94 |
Typical Hold Time | 0 Days | 5 Days |
Enterprise Value | $9.76B | $25.63B |
Dividend Yield | — | 0.64% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
XP Inc. trades at $31.38, down 3.74% today but remains near recent highs. The stock shows strong fundamental performance with 63.12% net income margin and 22.58% ROE, supported by consistent earnings beats in recent quarters. Technical indicators show mixed signals with bullish moving averages but overbought RSI readings. Analyst sentiment remains strongly positive with 80% buy ratings and price targets suggesting significant upside potential from current levels.
The outlook for XP remains favorable given its robust profitability metrics and growing revenue base, though investors should monitor competitive pressures and market volatility. The company's strong cash flow generation and institutional support provide stability, while technical overbought conditions suggest potential near-term consolidation before further upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Globus Medical Inc. Class A Common Stock
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →About XP Inc. Class A Common Stock
XP Inc. provides investment products and financial services in Brazil. Its platform includes brokerage, investment funds, fixed-income products, banking, insurance, and retirement solutions.
Read more on XP →
